WO2008156827A3 - Molecular grading methods for ductal carcinoma in situ - Google Patents

Molecular grading methods for ductal carcinoma in situ Download PDF

Info

Publication number
WO2008156827A3
WO2008156827A3 PCT/US2008/007699 US2008007699W WO2008156827A3 WO 2008156827 A3 WO2008156827 A3 WO 2008156827A3 US 2008007699 W US2008007699 W US 2008007699W WO 2008156827 A3 WO2008156827 A3 WO 2008156827A3
Authority
WO
WIPO (PCT)
Prior art keywords
situ
ductal carcinoma
methods
molecular
grading methods
Prior art date
Application number
PCT/US2008/007699
Other languages
French (fr)
Other versions
WO2008156827A2 (en
Inventor
Paul S Meltzer
Sean Davis
Rosemary L Balleine
Lucy R Webster
Christine L Clarke
Original Assignee
Us Gov Health & Human Serv
Paul S Meltzer
Sean Davis
Rosemary L Balleine
Lucy R Webster
Christine L Clarke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Paul S Meltzer, Sean Davis, Rosemary L Balleine, Lucy R Webster, Christine L Clarke filed Critical Us Gov Health & Human Serv
Publication of WO2008156827A2 publication Critical patent/WO2008156827A2/en
Publication of WO2008156827A3 publication Critical patent/WO2008156827A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The instant invention provides methods for determining the molecular grade of ductal carcinoma in situ in a subject through molecular profiling. Included in the invention are methods of prognosis and diagnosis of, and methods of determining therapeutic compounds. Also included in the invention are kits.
PCT/US2008/007699 2007-06-20 2008-06-20 Molecular grading methods for ductal carcinoma in situ WO2008156827A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93652607P 2007-06-20 2007-06-20
US60/936,526 2007-06-20

Publications (2)

Publication Number Publication Date
WO2008156827A2 WO2008156827A2 (en) 2008-12-24
WO2008156827A3 true WO2008156827A3 (en) 2009-03-26

Family

ID=39739338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/007699 WO2008156827A2 (en) 2007-06-20 2008-06-20 Molecular grading methods for ductal carcinoma in situ

Country Status (1)

Country Link
WO (1) WO2008156827A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106202969A (en) * 2016-08-01 2016-12-07 东北大学 A kind of tumor cells typing prognoses system

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2617434T3 (en) 2009-03-18 2017-06-19 Oncotherapy Science, Inc. NEIL3 peptides and vaccines that include them

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001011369A1 (en) * 1999-08-10 2001-02-15 Pangene Corporation Cancer treatments and diagnostics utilizing rad51 related molecules and methods
US20020039754A1 (en) * 1997-03-19 2002-04-04 Oncotech, Inc. Methods for cancer prognosis and diagnosis
WO2005000087A2 (en) * 2003-06-03 2005-01-06 Chiron Corporation Gene products differentially expressed in cancerous colon cells and their methods of use ii

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039754A1 (en) * 1997-03-19 2002-04-04 Oncotech, Inc. Methods for cancer prognosis and diagnosis
WO2001011369A1 (en) * 1999-08-10 2001-02-15 Pangene Corporation Cancer treatments and diagnostics utilizing rad51 related molecules and methods
WO2005000087A2 (en) * 2003-06-03 2005-01-06 Chiron Corporation Gene products differentially expressed in cancerous colon cells and their methods of use ii

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"AFFYMETRIX CATALOG; PRODUKT: HUMAN GENOME U133A ARRAY; ARRAY FINDER", AFFYMETRIX PRODUCT CATALOG, XX, XX, 1 July 2002 (2002-07-01), pages 1, XP002267612 *
ABRAHAM JACINTH ET AL: "Eme1 is involved in DNA damage processing and maintenance of genomic stability in mammalian cells.", THE EMBO JOURNAL 17 NOV 2003, vol. 22, no. 22, 17 November 2003 (2003-11-17), pages 6137 - 6147, XP002496100, ISSN: 0261-4189 *
BIRCAN ET AL: "CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: An immunohistochemistry-based pilot study", PATHOLOGY RESEARCH AND PRACTICE, GUSTAV FISCHER, STUTTGART, DE, vol. 202, no. 8, 10 August 2006 (2006-08-10), pages 569 - 576, XP005562179, ISSN: 0344-0338 *
DATABASE EMBL "Human colon cancer differentially expressed polynucleotide SEQ ID NO: 8985", XP002496103, Database accession no. ACL62850 *
GOEPEL C ET AL: "Tenascin-A marker for the malignant potential of preinvasive breast cancers.", GYNECOLOGIC ONCOLOGY DEC 2000, vol. 79, no. 3, December 2000 (2000-12-01), pages 372 - 378, XP002496101, ISSN: 0090-8258 *
HANNEMANN JULIANE ET AL: "Classification of ductal carcinoma in situ by gene expression profiling", BREAST CANCER RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 8, no. 5, 30 October 2006 (2006-10-30), pages R61, XP021027007, ISSN: 1465-5411 *
PORTER DALE ET AL: "Molecular markers in ductal carcinoma in situ of the breast.", MOLECULAR CANCER RESEARCH : MCR MAR 2003, vol. 1, no. 5, March 2003 (2003-03-01), pages 362 - 375, XP002496102, ISSN: 1541-7786 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106202969A (en) * 2016-08-01 2016-12-07 东北大学 A kind of tumor cells typing prognoses system

Also Published As

Publication number Publication date
WO2008156827A2 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
WO2009036427A3 (en) Prostate cancer biomarkers
WO2009108860A3 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2010009337A3 (en) Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
WO2008153705A3 (en) Methods of treating, diagnosing and detecting fgf21-associated disorders
WO2008011519A3 (en) Amigo-2 inhibitors for treating, diagnosing or detecting cancer
WO2006089125A3 (en) Methods of detecting ovarian cancer
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2010099161A8 (en) Micrornas in never-smokers and related materials and methods
WO2007076439A3 (en) Methods and marker combinations for screening for predisposition to lung cancer
MX2010000405A (en) Drug selection for lung cancer therapy using antibody-based arrays.
HK1145342A1 (en) Prognosis prediction for melanoma cancer
WO2008054828A3 (en) Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
NO20083397L (en) Anti-EphB4 antibodies and methods for their use
WO2008061020A3 (en) Methods of treating, diagnosing or detecting cancer
WO2008097466A3 (en) Metastasis specific splice variants of mena and uses thereof in diagnosis, prognosis and treatment of tumors
WO2009140039A3 (en) Synthetic antibodies
DK2211180T3 (en) Use of protein SATB2 as a marker to distinguish colorectal cancer from other cancers
WO2007120787A3 (en) Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression
WO2010120143A3 (en) Marker for prognosis of liver cancer
WO2005080593A8 (en) P53 wild-type as biomarker for the treatment with mtor inhibitors in combination with a cytotoxic agent
WO2013057581A3 (en) Composite biomarkers for non-invasive screening, diagnosis and prognosis of colorectal cancer
BRPI0811092A2 (en) METHOD OF DETERMINING A TUMOR DEGREE
WO2010009074A3 (en) Method for predicting and detecting tumor metastasis
ATE525484T1 (en) SLCO1B3 GENOTYPE
WO2013062261A3 (en) Newly identified colon cancer marker and diagnostic kit using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08768669

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08768669

Country of ref document: EP

Kind code of ref document: A2